DYAX 13.20 Dyax Corp $DYAX Hit a 52 week high of 13.50

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 11:49 AM

DYAX 13.20 Dyax Corp $DYAX Hit a 52 week high of 13.50 Closing the day 09:45 at 13.20 -0.14 -1.05% With a day low of 13.28 and a total volume of 41,988.

DYAX Recent Posts: http://investorshangout.com/Dyax-Corp-DYAX-53955/

DYAX Dyax Corp Recent Headline News

Dyax Up 73.8% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Mon Nov 10, 4:46PM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 6 months, Dyax has returned 73.76% as of today's recent price of $13.18.
DYAX: 12.94 (-0.40)

Why Dyax (DYAX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:42AM CST
Dyax's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
DYAX: 12.94 (-0.40)

Can Dyax (DYAX) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:49AM CST
Dyax possess a positive long term growth rate and favorable Zacks Rank
DYAX: 12.94 (-0.40)

Dyax Shares Up 62.1% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 62.07% as of today's recent price of $12.29.
DYAX: 12.94 (-0.40)

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Business Wire - Mon Nov 03, 6:30AM CST
Dyax Corp. (NASDAQ: DYAX) today announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks.
DYAX: 12.94 (-0.40)

BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 304.20 (-13.78), AMAG: 34.48 (+0.24), BIND: 9.95 (+0.04), DYAX: 12.94 (-0.40)

Update: Biotech Dyax Exceeds Q3 Estimates With The Future Looking Bright
David Zanoni - at Seeking Alpha - Thu Oct 30, 11:15AM CDT

DYAX: 12.94 (-0.40)

Will Dyax (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:04AM CDT
Will Dyax (DYAX) Continue to Surge Higher?
DYAX: 12.94 (-0.40)

Dyax ups earnings 87% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:53AM CDT

DYAX: 12.94 (-0.40)

Dyax's (DYAX) CEO Gustav Christiansen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 7:54PM CDT

DYAX: 12.94 (-0.40)

Dyax beats Street 3Q forecasts
Automated Insights - Tue Oct 28, 4:48PM CDT
BURLINGTON, Mass. (AP) _ Dyax Corp. (DYAX) on Tuesday reported a loss of $816,000 in its third quarter.
DYAX: 12.94 (-0.40)

Dyax (DYAX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:55PM CDT

DYAX: 12.94 (-0.40)

Dyax beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:16PM CDT

DYAX: 12.94 (-0.40)

Dyax Corp. Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:01PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers -including the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 12.94 (-0.40)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:35PM CDT

EA: 41.47 (+0.03), BXP: 127.40 (-0.44), AMP: 130.03 (unch), MRCY: 13.36 (-0.05), BLDP: 2.35 (-0.15), ESRX: 78.19 (+0.29), AJG: 47.94 (+0.02), NANO: 14.61 (+0.31), CAP: 22.26 (-0.10), EXTR: 3.68 (-0.01), HTA: 12.37 (-0.06), AEC: 19.71 (+0.16), MCK: 205.22 (+0.40), BGFV: 13.39 (+0.07), FB: 74.62 (+0.37), ARI: 16.49 (+0.04), EXP: 85.92 (+0.95), MWA: 9.68 (-0.05), DYAX: 12.94 (-0.40), FARO: 55.65 (+0.03), NFX: 32.90 (unch), KONA: 22.67 (-0.18), AZPN: 37.26 (+0.25), GILD: 102.12 (-2.08), HIW: 42.00 (-0.10), PEI: 22.24 (+0.11), GFIG: 4.85 (unch), CHRW: 73.76 (+0.65), HURN: 69.85 (+0.74), DLR: 68.88 (-0.18), HLIT: 6.79 (unch), AMCC: 5.95 (-0.14), INVN: 13.59 (-0.25), BOOM: 17.05 (+0.21), CINF: 51.36 (-0.01), KIM: 24.65 (-0.09), OI: 25.33 (-0.22), GPRE: 33.38 (+0.37), EPR: 56.55 (-0.18), APC: 89.02 (-0.44), IPHI: 13.64 (-0.34), HTS: 19.09 (+0.08), MAR: 78.16 (+0.07), INAP: 8.06 (+0.04), CRAY: 34.17 (+0.11), FEIC: 83.17 (+1.19), FISV: 70.50 (+0.13), DNB: 124.98 (-0.08), AFG: 60.36 (-0.02), CEB: 74.45 (+0.08), KEYW: 10.93 (+0.11), PLT: 51.57 (-0.03), MAC: 68.38 (+0.03), CHMT: 23.07 (-0.29), AFL: 59.07 (-0.07), CBT: 46.02 (-0.92), EIX: 62.08 (+0.40), EQR: 69.70 (-0.28)

Shares of DYAX Up 41.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 27, 9:38AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 41.60% as of today's recent price of $10.74.
DYAX: 12.94 (-0.40)

Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 13.65 (-0.10), BCRX: 10.08 (-0.31), NBIX: 18.88 (-0.26), ONTY: 1.63 (-0.05), DYAX: 12.94 (-0.40)

Dyax Has Returned 31.6% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Oct 20, 9:12AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 31.58% as of today's recent price of $9.98.
DYAX: 12.94 (-0.40)

Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast
Business Wire - Tue Oct 14, 7:00AM CDT
Dyax Corp. (NASDAQ

YAX) will host a webcast and conference call, including an open question and answer session, Tuesday, October 28, 2014. During the call, management will discuss the Company's financial results for the third quarter 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 12.94 (-0.40)

Dyax Up 25.6% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Fri Oct 10, 5:12PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 25.64% as of today's recent price of $9.53.
DYAX: 12.94 (-0.40)

Dyax Corp. (DYAX) Stock Research Links

DYAX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NOVOSENSE's Bold Performance Amid Rapid IC Demand

Surge in Revenue Growth Marks a Milestone for NOVOSENSE Give a pat on the back to NOVOSENSE (HKEX: 02676), because reporting a robust 66.73% bump in first-half revenue isn't small potatoes in today's tech landscape. This translates to around $374.54 million rolling into their coffers, which is quite a spectacle if you're watching the trend of sequential revenue growth...

Cypress Wood's Resilience in Louisiana's Humidity

Timber Talk with Wes McAdams Diving into the nitty-gritty of building materials isn't everyone's cup of tea, but when you live in a place like Baton Rouge, understanding what stands up to the swampy summer heat is plain survival. The main focus? Cypress wood. Now, Wes McAdams from Cajun Cypress throws his hat into the ring, shedding some light on why cypress might just be...

Eyepic 2-in-1 Camera Innovates at IFA 2026

Call me a sucker for new tech but what Hohem just unveiled might flip content creation on its head. Welcome the Eyepic—a 2-in-1 pocket gimbal camera stirring things up at IFA 2026 in Berlin. Now, maybe your eyeballs are glazing over with all the camera announcements flooding the market. I get it. Yet, this gadget isn’t just another add-on; it's a sneaky move by Hohem...

Decaf Coffee Market Grows to $5.2B by 2031 Amidst Tech Advances

The java crowd is waking up to a new trend that's more than just a flash in the mug. We're looking at a market shift where the decaffeinated coffee scene is steaming ahead, geared up for a whopping $5.2 billion valuation by 2031, growing at a tidy 7% CAGR. Yeah, you read that right. So, what's brewing that's making this market percolate? Riding the Wave of...

Money Market Funds Surge to Record $7.98 Trillion

When Money Talks Fast: Market Funds Smash Records Picture this: money market funds have surged to an eye-watering $7.98 trillion. That's a lot of zeros, folks. And it's not just the usual humdrum growth; we're talking a hefty $44.75 billion increase in just one week, thanks to a cocktail of government funds and prime fund muscle, as the Investment Company Institute (ICI)...

Bucket List Wine Dinners Beckon to Los Angeles

Sipping on the Extraordinary: LA Wine Soiree When was the last time you had a glass of wine that truly feels like you've unlocked a treasure chest? That's what LearnAboutWine.com is going for with their bucket list wine dinners in Los Angeles. Imagine tasting some of the world's most coveted bottles, all served with a level of polish that screams high-end dining. Led by...

Hamamatsu & AIxMed to Automate Cytology Workflows

Why This Collaboration Matters Here comes an interesting tidbit from the world of cytology: Hamamatsu and AIxMed are banding together to tackle workflow inefficiencies. Picture this—two powerhouses coming together to create a tool that might just relieve lab technicians from the tedious task of manually checking cytology slides. In a world where efficiency is king, this...

Roborock Expands into Pool Cleaning, Partners with Real Madrid

Roborock's Strategic Leap at IFA 2026 Ah, Roborock—those smart folks who want to squeeze every second out of your day—even if it means they have to steam-blast your tile floor to free you up for something else. They've strutted their stuff at IFA 2026, and I'm not just talking robot vacuums clunking through living rooms. Nope. They're diving into pools now. What’s...

China Expo Spotlights AI's Role in Future Electronics

AI Tech Takes Center Stage in Qingdao Kicking off the week, the 2026 China International Consumer Electronics Exposition unfolds its grand spectacle in Qingdao. Now, we're not just talking your average tech fare here—this is a heavyweight event with over 300 titans from 12 countries sprawling across a hefty 60,000 square meters. And those are numbers that make people...

BRP's C-Suite Shakeup: What It Means for Investors

Passing the Baton in BRP's Financial Helm Alright, folks, grab your coffee and listen up. There's a shakeup coming from the cold corners of Valcourt, Quebec—BRP Inc., the powersports behemoth on the TSX: DOO, has announced a changing of the guard in their finance department. Come October 1st, there's a planned power shift as Sébastien Martel steps down as CFO, passing...